Intercept Pharmaceuticals, Inc.

DB:I4P Stock Report

Market Cap: €742.1m

Intercept Pharmaceuticals Management

Management criteria checks 3/4

Intercept Pharmaceuticals' CEO is Jerry Durso, appointed in Jan 2021, has a tenure of 2.83 years. total yearly compensation is $4.46M, comprised of 16% salary and 84% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €919.29K. The average tenure of the management team and the board of directors is 2.7 years and 8.7 years respectively.

Key information

Jerry Durso

Chief executive officer

US$4.5m

Total compensation

CEO salary percentage16.0%
CEO tenure2.8yrs
CEO ownership0.1%
Management average tenure2.7yrs
Board average tenure8.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jerry Durso's remuneration changed compared to Intercept Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$159m

Mar 31 2023n/an/a

-US$173m

Dec 31 2022US$4mUS$715k

-US$175m

Sep 30 2022n/an/a

-US$202m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$8mUS$691k

-US$136m

Sep 30 2021n/an/a

-US$144m

Jun 30 2021n/an/a

-US$193m

Mar 31 2021n/an/a

-US$231m

Dec 31 2020US$4mUS$600k

-US$273m

Sep 30 2020n/an/a

-US$321m

Jun 30 2020n/an/a

-US$339m

Mar 31 2020n/an/a

-US$347m

Dec 31 2019US$4mUS$573k

-US$345m

Sep 30 2019n/an/a

-US$335m

Jun 30 2019n/an/a

-US$314m

Mar 31 2019n/an/a

-US$318m

Dec 31 2018US$3mUS$541k

-US$309m

Sep 30 2018n/an/a

-US$333m

Jun 30 2018n/an/a

-US$341m

Mar 31 2018n/an/a

-US$352m

Dec 31 2017US$4mUS$441k

-US$360m

Compensation vs Market: Jerry's total compensation ($USD4.46M) is above average for companies of similar size in the German market ($USD1.19M).

Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.

CEO

Jerry Durso (55 yo)

2.8yrs

Tenure

US$4,455,463

Compensation

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...

Leadership Team

NamePositionTenureCompensationOwnership
Jerome Durso
President2.8yrsUS$4.46m0.12%
€ 919.3k
Andrew Saik
Chief Financial Officer2.4yrsUS$1.39m0.055%
€ 408.4k
Jared Freedberg
General Counsel2.8yrsUS$1.31m0.13%
€ 1.0m
Linda Richardson
Executive VP & Chief Commercial Officer2.8yrsUS$1.34m0.040%
€ 296.4k
M. Berrey
President of Research & Development and Chief Medical Officer2.4yrsUS$1.61m0.068%
€ 503.0k
Rocco Venezia
Chief Accounting Officer & Treasurer2.7yrsUS$856.23k0.061%
€ 451.6k
Nareg Sagherian
Executive Director of Global Investor Relations1.9yrsno datano data
David Ford
Chief Human Resources Officer6.5yrsUS$1.91m0.036%
€ 266.8k
Mark Pruzanski
Founder2.8yrsUS$6.43m1.48%
€ 11.0m
Paul Nitschmann
Senior Vice President of Regulatory Affairsno datano datano data
Kathleen Munster
Chief Quality Officer & SVP of Technical Operationsless than a yearno datano data
Michael Blash
Senior Vice President of Corporate Affairsless than a yearno datano data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Management: I4P's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jerome Durso
President2.5yrsUS$4.46m0.12%
€ 919.3k
Mark Pruzanski
Founder21.8yrsUS$6.43m1.48%
€ 11.0m
Daniel Bradbury
Independent Chairman7.3yrsUS$327.39k0.056%
€ 417.8k
Glenn Sblendorio
Independent Director9.8yrsUS$332.39k0.056%
€ 416.0k
Luca Benatti
Independent Director9.3yrsUS$327.39k0.061%
€ 452.2k
Srinivas Akkaraju
Independent Director11.1yrsUS$317.39k0.091%
€ 672.2k
Gino Santini
Lead Independent Director8yrsUS$337.39k0.057%
€ 419.5k
Alan Hofmann
Member of the Scientific Advisory Boardno datano datano data
Scott L. Friedman
Member of the Scientific Advisory Boardno datano datano data
Massimo Pinzani
Member of the Scientific Advisory Boardno datano datano data
Aldo Roda
Member of the Scientific Advisory Boardno datano datano data
Keith Gottesdiener
Independent Director7.3yrsUS$322.39k0.059%
€ 438.6k

8.7yrs

Average Tenure

62yo

Average Age

Experienced Board: I4P's board of directors are considered experienced (8.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/09 01:36
End of Day Share Price 2023/11/07 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intercept Pharmaceuticals, Inc. is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Geoffrey MeachamBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.